Strategic partnerships Somerset Therapeutics is expanding its U.S. footprint through new license and supply agreements with Medichem, signaling a growing willingness to collaborate with contract manufacturers and suppliers to scale injectable and ophthalmic products in the US market.

Growth potential With revenue in the low single digits and a lean employee base, the company appears open to incremental scale and external partnerships to accelerate product development, manufacturing capacity, and market reach in sterile injectables and ophthalmics.

US market focus The emphasis on the U.S. healthcare market presents strong sales opportunities for partners with regulatory, distribution, and commercial capabilities to expand access to Somerset’s sterile injectable and ophthalmic portfolios.

Technology footprint A web-centric tech stack indicates modern digital presence and potential for streamlined customer interactions, e-commerce enablement for collaboration, and digital marketing alignment with sales outreach.

Competitive landscape Operating alongside large pharma players like Amneal, Teva, Lupin, and Sandoz, Somerset could benefit from niche partnership models and co-development opportunities to differentiate through specialty sterile and ophthalmic products.